Clinical trials: Movement Abnormalities
Dystonia
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.
- Trial name
- NCT07304089
- Testing
- VIM0423
- Where
- 45 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Vima Therapeutics
Parkinson's Disease
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.
- Trial name
- NCT02006290
- Testing
- PF-06412562
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Parkinson's Disease
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
This is a two-arm, double-blind, placebo-controlled study.
- Trial name
- NCT00566462
- Testing
- perampanel
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Eisai Inc.
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
BradyXplore Phase II: Bradykinesia Feature Extraction System
Study objectives are to improve motion sensor algorithms for measuring bradykinesia in the clinic and the home, evaluate test-retest reliability of motion sensor algorithms for measuring bradykinesia compared to clinician raters…
- Trial name
- NCT02358876
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Huntington Disease
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
- Trial name
- NCT06254482
- Testing
- Votoplam
- Where
- 24 sites in Australia, Austria and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Syndrome
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
- Trial name
- NCT01950468
- Testing
- NAV5001, DaTscan
- Where
- 2 sites in United States
- Sponsor
- Navidea Biopharmaceuticals
Parkinson's Disease, Essential Tremor
Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
This is a 6-week exploratory clinical study, designed to test whether treatment with peroneal electrical trans-cutaneous stimulation can have a beneficial effects on symptoms associated with Parkinson's diseases and essential…
- Trial name
- NCT06036368
- Testing
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
- Where
- Czechia
- Volunteers
- 23 people
- Sponsor
- Stimvia s.r.o.
Parkinson Disease
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD.
- Trial name
- NCT00228150
- Testing
- SR57667B
- Where
- 13 sites in Austria, Canada and 11 more
- Volunteers
- 564 people
- Sponsor
- Sanofi
Health Volunteers, Huntington Disease
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted
- Trial name
- NCT03019289
- Testing
- pridopidine (90 mg)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Prilenia
Parkinson Disease
Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation
The primary objective is to characterize the programming effects of Boston Scientific Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of Parkinson's disease in acute and chronic settings.
- Trial name
- DIRECT-DBS (NCT02835274)
- Testing
- BSC Deep Brain Stimulation System with Directional Lead
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Boston Scientific Corporation
Orthostatic Hypotension, Parkinson's Disease
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease.
- Trial name
- 306A/306B (NCT01176240)
- Testing
- Droxidopa
- Where
- 60 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chelsea Therapeutics
Huntington Disease
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
This is the first clinical study of VY-HTT01, a gene therapy for early-stage Huntington's Disease (HD) patients. The primary goal of this trial is to evaluate the safety and tolerability of VY-HTT01.
- Trial name
- NCT04885114
- Testing
- Intraparenchymal rAAV1 - (mi)RNA HTT
- Sponsor
- Voyager Therapeutics
Huntington's Disease
Escalating Dose Study in Healthy Volunteers With SEN0014196
This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics of single and multiple escalating doses of SEN0014196.
- Trial name
- NCT01521832
- Testing
- SEN0014196
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Siena Biotech S.p.A.
Parkinson's Disease
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease
- Trial name
- NCT02728947
- Testing
- ROTIGOTINE
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Luye Pharma Group Ltd.
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Parkinson's Disease With End of Dose Wearing Off
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
- Trial name
- NCT00219284
- Testing
- Carbidopa/levodopa/entacapone
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 359 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
- Trial name
- NCT00163085
- Testing
- NR2B NMDA Antagonist CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.